Richmond Pharmacology is excited to join the JSCTR Annual Meeting 2026 in Kobe, Japan, on 19–21 February 2026.

Bringing together leaders in clinical research, regulatory science, and trial operations, JSCTR serves as a key platform for advancing high‑quality clinical trials, promoting innovation in study design, and strengthening global collaboration across the clinical research community.

Representing Richmond Pharmacology:

  • Dr Jörg Taubel, Chief Executive Officer
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

‍

Our Focus at the Conference

  • Innovations in clinical trial methodology
  • Regulatory harmonisation and emerging guidance
  • Best practices in global trial operations
  • Patient‑centric strategies in clinical development
  • Collaboration between academia, industry, and regulatory stakeholders

Connect With Us

If you are attending JSCTR 2026 and would like to explore partnership or development opportunities:

📧 japanbd@richmondpharmacology.com

‍

Learn more here: Japanese Society of Clinical Trials (JSCTR)

‍

Latest news

Richmond Pharmacology highlights encouraging first-in-human results for Regeneron's investigational RNAi therapy in MASLD

November 12, 2026
NEJM publication and AASLD presentation reports that 79% of treated participants with MASLD and available measurements achieved normal liver fat levels at Week 24 after a single dose of CIDEBsiRNA, alongside improvements in markers of liver injury.
Read more

Upcoming Event

AHA Scientific Sessions 2026

14 - 16 November 2026
Richmond Pharmacology is excited to join the AHA Scientific Sessions 2026 in 14–16 November 2026, on 14–16 November 2026, hosted by the American Heart Association.
View event